Recruiting
Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer
This is a randomized, controlled study to assess the effect of Sidekick Health's digital program on self-efficacy and medication adherence in breast cancer patients prescribed adjuvant anti-hormonal treatment. Participants will be treated with the digital program in addition to standard of care (SoC), or SoC only.
ClinicalTrials.gov IDNCT06989450
PhaseNA
Enrollment140
SponsorSidekick Health
Age18 Years
SexFEMALE
Conditions studied
Breast Cancer, Cancer
About this study
This is a randomized, controlled study to assess the effect of Sidekick Health's digital program on self-efficacy and medication adherence in breast cancer patients prescribed adjuvant anti-hormonal treatment. Participants will be treated with the digital program in addition to standard of care (SoC), or SoC only.
Interventions
- Device: Sidekick digital patient support program for patients with breast cancer — A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
- Other: Standard of care for breast cancer patients — Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation
Primary outcomes
- Self-efficacy and health education impact (12 weeks from baseline)
Eligibility information
Inclusion Criteria:
* Adult patient (18 years or older) diagnosed with breast cancer of stage I, II or III from 1st September 2023 or later
* Have been prescribed adjuvant endocrine therapy for breast cancer.
* Understands written and spoken Icelandic or English.
* Owns a smart-phone compatible with the Sidekick app and capable to use it
* Willing to download the Sidekick app on the smart-phone and to comply with the study measures and visits according to the protocol.
* Capable of providing informed consent for participating in the study.
Exclusion Criteria:
* Having other concurrent conditions that in the opinion of the oncologist may compromise patient safety or study objectives.
* Concurrent participation in another clinical study in which the study treatment may confound the evaluation of the investigational program.
* Metastatic breast cancer (stage IV)
* Previous experience with Sidekick breast cancer program
Study locations
- Landspitali University Hospital, Reykjavik, 101 Iceland
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.